Check back often to find the latest news on AgeneBio and our pipeline of multiple candidates.
April 23, 2024
AgeneBio Founder Michela Gallagher Presents Hope4MCI Results at 12th Alzheimer’s & Parkinson’s Drug Development Summit
Examining Progression in MCI Due to AD: Results from a Phase 2b Trial of AGB101
- Using high resolution structural brain imaging to monitor brain atrophy as a biomarker of progression
- Consistent with a decrease in clinical and cognitive progression (CDR sum of boxes), brain atrophy was reduced by AGB101 compared to placebo in a 78-week double-blind randomized controlled study
- Topography of this effect was consistent with the prodromal phase of amnestic MCI (e.g. reducing atrophy of entorhinal cortex)
